Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07HUW
|
|||
| Former ID |
DNCL002547
|
|||
| Drug Name |
Oregovomab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [1] | |
| Epithelial ovarian cancer [ICD-11: 2B5D; ICD-9: 183] | Phase 2 | [2] | ||
| Company |
Quest PharmaTech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ovarian carcinoma antigen CA125 (MUC16) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.